Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS

Trial Profile

Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Vildagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jun 2015 Primary end point (glycemic variability indices) met as per the abstract published in 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top